Editas Medicine, Inc. (EDIT) Revenue Growth
Editas Medicine, Inc. (EDIT) year-over-year revenue growth rate history. Analyze revenue growth in Excel with MarketXLS.
Revenue Growth Data
| Period | YoY Revenue Growth |
|---|---|
| 2017-12-31 | 126.80% |
| 2018-12-31 | 132.64% |
| 2019-12-31 | -35.71% |
| 2020-12-31 | 341.93% |
| 2021-12-31 | -71.85% |
| 2022-12-31 | -22.83% |
| 2023-12-31 | 296.32% |
| 2024-12-31 | -58.64% |
| 2025-12-31 | 25.39% |
How EDIT compares with sector peers
| Symbol | Company | Revenue growth (latest fiscal year) |
|---|---|---|
| NTRA | Natera Inc. | 35.90% |
| KURA | Kura Oncology Inc. | 25.24% |
| MNKD | MannKind Corporation | 22.23% |
| NBIX | Neurocrine Biosciences Inc. | 21.45% |
| INCY | Incyte Corporation | 21.22% |
These are five companies in the same sector as EDIT with a comparable annual revenue growth. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Editas Medicine, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue_Growth("EDIT", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | EDIT | $3.15 | +2.33% | 0.86M |
| 3 | ||||
| 4 | ||||
| 5 |